Antipsychotic induced metabolic abnormalities: An interaction study with various PPAR modulators in mice

Life Sciences

Volumn 79, Issue 19, 2006, Pages 1865-1872

  Arulmozhi, D K ^a,b   Dwyer, D S ^c   Bodhankar, S L ^b  

^a LUPIN LIMITED   (India)

^b BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^c Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Clozapine; Dyslipidemia; Hyperglycemia; PPAR; Ziprasidone

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CHLORPROMAZINE; CLOZAPINE; FENOFIBRATE; GLIMEPIRIDE; INSULIN; NEUROLEPTIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; PROTEIN INTERACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC DISEASES; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TRIGLYCERIDES;

ANIMALIA;

EID: 33748978997     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.06.016     Document Type: Article

References (47)

1. Ardizzone T.D., Bradley R.J., Freeman III A.M., and Dwyer D.S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Research 923 (2001) 82-90
2. Arjona A.A., Zhang S.X., Adamson B., and Wurtman R.J. An animal model of antipsychotic-induced weight gain. Behavioural Brain Research 152 (2004) 121-127
3. Arneson G.A. Phenothiazine derivatives and glucose metabolism. Journal of Neuropsychiatry 5 (1964) 181-185
4. Baptista T., Kin N.M.K.N.Y., Beaulieu S., and de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002) 205-219
5. Berger J.P., Akiyama T.E., and Meinke P. PPARs: therapeutic targets for metabolic disease. Trends in Pharmacological Sciences 26 (2005) 244-251
6. Best L., Yates A.P., and Reynolds G.P. Actions of antipsychotic drugs on pancreatic β-cell function: contrasting effects of clozapine and haloperidol. Journal of Psychopharmacology 19 (2005) 597-601
7. Chaouloff F., Laude D., and Baudrie V. Effects of the 5-HT1C/5-HT2 receptor agonist DOI and α-methyl-5-HT on plasma glucose and insulin levels in the rat. European Journal of Pharmacology 187 (1990) 435-443
8. Chaput E., Saladin R., Silvestre M., and Edgar A.D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochemical and Biophysical Research Communications 271 (2000) 445-450
9. Cheng C.Y., Hong C.J., and Tsai S.J. Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice. Life Sciences 76 (2005) 2269-2273
10. Cope M.B., Nagy T.R., Fernandez J.R., Geary N., Casey D.E., and Allison D.B. Antipsychotic drug-induced weight gain: development of an animal model. International Journal of Obesity 29 (2005) 607-614
11. Dwyer D.S., and Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacology, Biochemistry and Behavior 75 (2003) 255-260
12. Engl J., Laimer M., Niederwanger N., Kranebitter M., Starzinger M., Pedrini M.T., Fleischhacker W.W., Patsch J.R., and Ebenbichler C.F. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Molecular Psychiatry 10 (2005) 1089-1096
13. Fukuen S., Iwaki M., Yasui A., Makishima M., Matsuda M., and Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor γ agonistic activity. Journal of Biological Chemistry 280 (2005) 23656-25659
14. Gottstater A., Ahmed M., Fernlund P., and Sundkvist G. Autonomic neuropathy in type 2 diabetic patients is associated with hyperinsulinemia and hypertriglyceridemia. Diabetic Medicine 16 (1999) 49-54
15. Guo L., and Tabrizchi R. Peroxisome proliferators-activated receptor gamma as a drug target for the pathogenesis of insulin resistance. Pharmacology & Therapeutics 111 (2006) 145-173
16. Gupta S., Lentz B., Lockwood K., and Frank B. Atypical antipsychotics and glucose dysregulation: a series of 4 cases. Primary Care Companion to the Journal of Clinical Psychiatry 3 (2001) 61-65
17. Hajduch E., Rencurel F., Balendran A., Batty I.H., Downes C.P., and Hundal H.S. Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. Journal of Biological Chemistry 274 (1999) 13563-13568
18. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., and Goff D.C. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five year naturalistic study. American Journal of Psychiatry 157 (2000) 975-981
19. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W., Treadway J.L., Gibbs E.M., Zawalich W.S., and Rollema H. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: role of muscarinic antagonism in antipsychotic induced diabetes and hyperglycemia. Diabetes 54 (2005) 1552-1558
20. Jones D., Ding X., and Daynes R. Nuclear receptor peroxisome proliferators-activated receptor alpha is expressed in resting murine lymphocytes. Journal of Biological Chemistry 277 (2002) 6838-68345
21. Kamran A., Doraiswamy P.M., and Jane J.L. Severe hyperglycemia associated with high doses of clozapine. American Journal of Psychiatry 151 (1994) 1395
22. Kostakoglu A.E., Yazici K.M., and Erbas T. Ketoacidosis as a side effect of clozapine: a case study. Acta Psychiatrica Scandinavica 93 (1996) 217-218
23. 1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003) 519-526
24. Lean M.E.J., and Pajonk F.G. Patients with antipsychotic drugs: another high risk group for type 2 diabetes. Diabetes Care 26 (2003) 1597-1605
25. Lefebvre P., Chinetti G., Fruchart J.C., and Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. The Journal of Clinical Investigation 116 (2006) 571-580
26. Lehrke M., and Lazar M.A. The many faces of PPARγ. Cell 123 (2006) 993-999
27. Lu X., and Dwyer D.S. Second generation antipsychotic drugs, olanzapine, quetiapine, and clozapine, enhance neurite outgrowth in PC12 cells via PI3K/Akt, ERK and pertussis toxin-sensitive pathways. Journal of Molecular Neuroscience 27 (2005) 43-64
28. Matsui-Sakata A., Ohtani H., and Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metabolism and Pharmacokinetics 20 (2005) 368-378
29. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., and Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
30. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70 (2004) 1-17
31. Minet-Ringuet J., Even P.C., Goubern M., Tome D., and de Beaurepaire R. Long term treatment with olanzapine mixed with food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46 (2006) 254-262
32. Moraes L.A., Piqueras L., and Bishop-Bailey D. Peroxisome proliferators-activated receptors and inflammation. Pharmacology & Therapeutics 110 (2006) 371-385
33. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43 (2000) 533-549
34. Norman D., and Hiestand W.A. Glycemic effects of chlorpromazine in the mouse, hamster and rat. Proceedings of the Society for Experimental Biology and Medicine 90 (1995) 89-91
35. Ota M., Mori K., Nakashima A., Kaneko Y.S., Takahashi H., and Ota A. Resistance to excessive bodyweight gain in risperidone-injected rats. Clinical and Experimental Pharmacology and Physiology 32 (2005) 279-287
36. Robinson K.A., Wasef S.Z.Y., and Buse M.G. At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30 (2006) 93-98
37. Ryall R.W. Some actions of chlorpromazine. British Journal of Pharmacology 11 (1956) 339-345
38. 3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods and Findings in Experimental and Clinical pharmacology 27 (2005) 289-304
39. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry 162 (2005) 1535-1538
40. Staehr P., Hother-Nielsen O., and Beck-Nielsen H. Hepatic glucose production: therapeutic target in type 2 diabetes?. Diabetes, Obesity and Metabolism 4 (2002) 215-223
41. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
42. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
43. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., and Julius D. Eating disorders and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374 (1995) 542-546
44. Tsuchida A., Yamauchi T., Takekawa S., Hada Y., Ito Y., Maki T., and Kadowaki T. Peroxisome Proliferator-Activated Receptor (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPAR α, PPAR γ, and their combination. Diabetes 54 (2005) 3358-3370
45. Wirshing D.A. Adverse effects of atypical antipsychotics. Journal of Clinical Psychiatry 62 (2001) 7-10
46. Wirshing D., Spellberg B., Erhart S., Marder S., and Wirshing W. Novel antipsychotics and new onset diabetes. Biological Chemistry 44 (1998) 778-783
47. Xie H., and Lautt W.W. Induction of insulin resistance by cholinergic blockade with atropine in the cat. Journal of Autonomic Pharmacology 15 (1995) 361-369